stock market report for today


Investment company Ausdal Financial Partners, Inc. buys VanEck Vectors Gold Miners, iPath S&P 500 VIX Short Term Futures TM ETN, Vanguard Short-Term Government ETF, sells Comcast Corp during the 3-months ended 2017-03-31, according to the most recent filings of the investment company, Ausdal Financial Partners, Inc.. As of 2017-03-31, Ausdal Financial Partners, Inc. owns 241 stocks with a total value of $203 million. These are the details of the buys and sells.

New Purchases: GDX, VXX, VGSH, Reduced Positions: CMCSA,


For the details of Ausdal Financial Partners, Inc.’s stock buys and sells, go to www.gurufocus.com/StockBuy.php?GuruName=Ausdal+Financial+Partners%2C+Inc.

These are the top 5 holdings of Ausdal Financial Partners, Inc.Vanguard FTSE Emerging Markets (VWO) – 267,451 shares, 4.71% of the total portfolio. iShares Core S&P Small-Cap (IJR) – 49,626 shares, 3.36% of the total portfolio. Vanguard Short-Term Corporate Bond ETF (VCSH) – 81,561 shares, 3.19% of the total portfolio. Caterpillar Inc (CAT) – 60,550 shares, 2.76% of the total portfolio. SPDR Bloomberg Barclays High Yield Bond (JNK) – 152,109 shares, 2.73% of the total portfolio. New Purchase: VanEck Vectors Gold Miners (GDX)


Ausdal Financial Partners, Inc. initiated holdings in VanEck Vectors Gold Miners. The purchase prices were between $20.92 and $25.57, with an estimated average price of $23.21. The stock is now traded at around $21.70. The impact to the portfolio due to this purchase was 0.75%. The holdings were 73,030 shares as of 2017-03-31.

stock market report for today: Norwegian Cruise Line Holdings Ltd.(NCLH)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Shares of Carnival have dropped 4.2% to $43.74 at 2:39 p.m. today, while Royal Caribbean Cruise (RCL) has tumbled 5.6% to $66.15, and Norwegian Cruise Line Holdings (NCLH) is off 4.3% at $38.63.

  • [By Dan Caplinger]

    The stock market once again proved its resiliency on Wednesday, bouncing back from extensive declines early in the session to recover most of its losses. The Dow Jones Industrials actually managed to post yet another record close with a modest gain, and although other major market benchmarks suffered declines, they weren’t significant. Moreover, some favorable news from certain pockets of the market helped bolster investor confidence. Toll Brothers (NYSE:TOL), Lantheus Holdings (NASDAQ:LNTH), and Norwegian Cruise Line Holdings (NASDAQ:NCLH) were among the top performers on the day. Below, we’ll look more closely at these stocks to tell you why they did so well.

  • [By Teresa Rivas]

    Norwegian Cruise Lines (NCLH) was up nearly 7% on Wednesday afternoon, following its fourth-quarter earnings report.

    Norwegian said that it earned 56 cents a share, a penny ahead of analysts’ expectations. Revenue rose 8.5% to $1.13 billion, also squeaking past the $1.11 billion consensus estimate.

    For the full year, Norwegian said it expects to earn between $3.75 and $3.85 a share, with a midpoint a penny above the $3.79 average analyst estimate. It’s first-quarter EPS guidance of 36 cents also came in ahead of the 34-cent consensus.


    Instinet analyst Harry Curtiswrites that after recent missteps, it was “vital” for Norwegian’s forecast to meet expectations but not seem too optimistic, a balancing act he believes the company achieved.

    He reiterated a Buy rating and $52 price target on the stock:

    NCLHs 2017 EPS outlook ($3.75 to $3.85) brackets our forecast ($3.75) and the Streets ($3.79). However, we believe there could be upside to that range, given the positive booking and pricing trends so far this year. We remain positive on the shares of NCLH, which we believe should continue to outperform through 2017.


    Norwegian was recently up 6.8% to $51.49.

  • [By Monica Gerson]

    Norwegian Cruise Line Holdings Ltd (NASDAQ: NCLH) is expected to report its quarterly earnings at $0.37 per share on revenue of $1.10 billion.

    Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is projected to post its quarterly earnings at $2.31 per share on revenue of $338.86 million.

stock market report for today: Mallinckrodt plc(MNK)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Mallinckrodt (MNK) tumbled to the bottom of the S&P 500 today after its earnings topped the Street consensus but offered commentary that spooked investors.

    Agence France-Presse/Getty Images

    Shares of Mallinckrodt dropped 9.1% to $52.42, while the S&P 500 rose 0.1%.

    Barclays analyst Douglas Tsao and Morgan Williams callMallinckrodt’s plunge “outsized.” They explain why:

    In our view the sell-off afterMallinckrodt reported CY3Q16 earnings is outsized considering much of the disclosure on the call was largely expected, including specialty generics weakness and the 2017 outlook, which seemed relatively mild. While outsized Acthar contribution to EBITDA may be accounting for some of the sell-off, wed argue that there is benefit to the brand outperforming, especially considering the need to offset Therakos production issues in CY4Q16 and CY1Q17 as well as specialty generics weakness. We recognize some lingering headline risk associated with media reports criticizing the cost of Acthar to Medicare, after CMS released its prescription drug spending dashboard.


    Mallinckrodt’s market capitalization fell to $5.7 billion today from $6.2 billion yesterday. It reported net income of $306 million on revenue of $3.3 billion in 2015.

    This marks the third time in less than two weeks that Mallinckrodt was the S&P 500′s biggest loser.

  • [By Keith Speights]

    Although 2016 wasn’t exactly the greatest year for healthcare stocks in general, there really aren’t very many true bargains to be found in the industry. However, three healthcare stocks do appear to be priced well below what they’re worth. Here’s why Gilead Sciences (NASDAQ:GILD), Lantheus Holdings (NASDAQ:LNTH), and Mallinckrodt (NYSE:MNK) look to be ridiculously cheap right now.

  • [By Ben Levisohn]

    Mallinckrodt (MNK) tumbled to the bottom of the S&P 500 today after Citron Research accused the company of fraud.

    Getty Images

    Mallinckrodt tumbled 12% to $59.60 today, while the S&P 500 declined 0.2% to 2,176.94.

    Leerink’s Jason Gerberry and Etzer Darout explain the allegations:

    Mallinckrodtshares are down -7-8% based on a short report citing CMS dashboard data which call into question Acthar Gel sales derived from government sources (CMS; Medicaid & Medicare). The report appears to overstate Acthar CMS sales as a percent of total product sales, as the methodology utilized by CMS drug spending dashboard for Medicare spend is based on gross sales, not net., although it’s unclear to what extent Acthar CMS sales are overstated.


    The report suggestsMallinckrodt mgmt understated combined Medicaid/Medicare sales on an investor call, saying it was about a little bit higher than a quarter of the business vs. gross sales on CMS dashboard implying sales were 61% of total Acthar net revenue (an apples to oranges comparison). We dont know the exact net sales of Acthar to Medicare/Medicaid, but we believe it is safe to assume Medicaid, after CPI price penalties had high discounts/rebates and assuming an 80% gross-to-net ratio on the Medicare book ($504m gross) suggests Acthar net sales would be closer to 38-45% range vs. the 61% figure cited in the short-report. Why this may matter Acthar Gel is an old product lacking good randomized, controlled data consistent with most products approved in the modern era. The report appears to be an attempt to call into question whether the government should be paying Acthars average $80-100k net price/patient/year by calling to this to the attention of government figures who have been targeting excessive drug pricing issues. This type of issue became a major headache for Mylan (MYL) investors recently with EpiPen.Mallinckrodt is presenting at a compe

stock market report for today: Rosetta Genomics Ltd.(ROSG)


Advisors’ Opinion:

  • [By Lisa Levin] Related CRMD Mid-Day Market Update: U.S. Stocks Turn Negative; AveXis Shares Spike Higher 12 Biggest Mid-Day Gainers For Tuesday CorMedix's (CRMD) CEO Khoso Baluch on Q4 2016 Results – Earnings Call Transcript (Seeking Alpha)
    Related BIOA Mid-Day Market Update: U.S. Stocks Turn Negative; AveXis Shares Spike Higher Mid-Morning Market Update: Markets Edge Higher; Tiffany Earnings Top Estimates BioAmber (BIOA) Q4 2016 Results – Earnings Call Transcript (Seeking Alpha)
    CorMedix Inc. (NYSE: CRMD) shares fell 27.5 percent to $1.50 after the company reported Q4 results and issued a business update.
    Bioamber Inc (NYSE: BIOA) shares tumbled 23.6 percent to $2.40. BioAmber reported FY16 adjusted loss of $1.07 per share on revenue of $8.3 million.
    The Medicines Company (NASDAQ: MDCO) shares dipped 20.9 percent to $41.62.
    Innocoll Holdings PLC (NASDAQ: INNL) shares fell 20.3 percent to $1.49. Innocoll posted a narrower-than-expected quarter loss, but revenue missed estimates. Stifel Nicolaus downgraded Innocoll from Buy to Hold.
    Rosetta Genomics Ltd. (USA) (NASDAQ: ROSG) shares declined 20.3 percent to $3.83. On Thursday, Rosetta Genomics disclosed a 1-for-12 reverse stock split.
    Esperion Therapeutics Inc (NASDAQ: ESPR) shares dropped 19.9 percent to $23.76. Esperion Therapeutics shares have jumped 106.19 percent over the past 52 weeks, while the S&P 500 index has gained 16.70 percent in the same period.
    AmTrust Financial Services Inc (NASDAQ: AFSI) tumbled 18.3 percent to $17.65. AmTrust Financial disclosed that it will delay its annual report filing for the fiscal year ended December 31, 2016.
    Qualstar Corporation (NASDAQ: QBAK) slipped 17.7 percent to $6.85. Qualstar reported a Q4 loss of $0.20 per share on revenue of $2.2 milli

stock market report for today: LG Display Co., Ltd.(LPL)


Advisors’ Opinion:

  • [By Anders Bylund, Chuck Saletta, and Brian Feroldi]

    According to comments by Universal Display CEO Steve Abramson, Samsung (NASDAQOTH:SSNLF) is pouring $9 billion into building OLED production facilities this year. LG Display (NYSE:LPL) expects more than half of its 2020 revenues to come from OLED panels. The OLED TV market is expected to grow sixfold in the next four years, and the lighting panel market is only just getting started.

  • [By Peter Graham]

    A long term performance chart shows shares of Corning Incorporated in a steady uptrend since we recommended the stock while Universal Display Corporation (NASDAQ: OLED) has taken off even higher and LG Display Co Ltd (NYSE: LPL) and AU Optronics Corp (NYSE: AUO) have given a similar performance:

stock market report for today: Nomura Holdings Inc ADR(NMR)

Advisors’ Opinion:

  • [By Maureen Farrell]

    Shortly after Lehman declared bankruptcy, Barclays (BCS) paid $1.3 billion for most of the firm’s North American operations, its Times Square headquarters, and about 9,000 employees. Nomura Holdings (NMR) paid roughly $200 million for Lehman’s operations in Asia.

stock market report for today: Intrexon Corporation(XON)

Advisors’ Opinion:

  • [By WWW.MONEYSHOW.COM]

    Intrexon (XON) has made a small yet strategic acquisition in buying GenVec (GNVC); with the purchase, XON gets AdenoVerse, a platform of adenovirus vectors for delivering drugs and vaccines that dovetails nicely with its existing suite of gene therapy technologies, suggests John McCamant, editor of The Medical Technology Stock Letter.

Leave a Reply

Your email address will not be published. Required fields are marked *